Health

SoftBank and Novartis-backed digital therapeutics provider Pear has agreed a reverse merger at a $1.6bn pro forma equity valuation.

Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.

Wake Forest University spinout Renovo closed the round at $6.4m and will put the funding into further development of its brain injury treatment system.

Matrix Partners China and Citic Private Equity Funds Management co-led the series B round, which will fund development of treatments for rare medical conditions.

The Cornell cardiovascular data technology spinout has launched with $54m in funding, $43m coming from an American College of Cardiology-backed series B round.

Lilly Asia Ventures and Baidu Ventures helped the drug discovery software provider push its overall funding past the $310m mark.

Bayer and Fujifilm scored exits as the cancer treatment developer floated on the Nasdaq Global Select Market at the top of its range.

The cardiovascular data technology developer has launched with $54m in funding, $43m coming from a Cigna Ventures-backed series B round.

Tencent, Credit Saison and JG Summit have all contributed to a $16m round for GrowSari while Greenvolt is set to acquire up to 29% of solar system installer Perfecta Energía.

The cancer therapy developer and Jackson Laboratory spinout floated at the upper end of its range and now has a $600m market cap.

Novo and Celgene will retain shares in the cancer therapy developer, which floated at the upper end of its range and which now has a $600m market cap.